Pacira Earnings Call Highlights Growth, Pipeline Momentum

Pacira ((PCRX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Pacira’s latest earnings call struck a notably upbeat tone, with management emphasizing broad-based growth across its non-opioid pain portfolio and a solid profitability profile. Executives acknowledged near-term noise from pricing, storms and higher spending, but framed these as tactical issues against a backdrop of expanding reimbursement, fortified patents and a maturing pipeline that together support a favorable medium-term outlook.

EXPAREL Growth Underpins Core Franchise

EXPAREL remained Pacira’s workhorse, posting Q1 2026 net sales of $143.3 million versus $136.5 million a year earlier, supported by roughly 7% volume growth. Management credited expanded reimbursement, a new J-code, growing non-opioid stewardship efforts and broader protocol adoption for sustaining momentum into the rest of 2026 despite some pricing headwinds.

ZILRETTA and ioverao Deliver Double-Digit Gains

ZILRETTA and ioverao continued to scale as complementary growth drivers, with Q1 sales rising 15% and 21% year over year to $26.8 million and $6.2 million respectively. Pacira highlighted the benefits of dedicated sales teams, patient access initiatives and strategic partnerships such as the J&J MedTech collaboration for ZILRETTA that is helping expand reach in targeted musculoskeletal markets.

Pipeline Progress and Near-Term Clinical Readouts

The company outlined a busy clinical calendar, led by gene therapy candidate PCRX201 for knee osteoarthritis, with Part A fully enrolled at 49 patients and top-line data expected later this year plus a roughly 90-patient Part B starting midyear. Enrollment has finished for the ZILRETTA Phase 3 shoulder osteoarthritis study, while PCRX2002 is slated for Phase 2 initiation and ioverao’s spasticity registrational trial targets year-end results.

Stronger Patent Wall for EXPAREL

Pacira underscored a significant reinforcement of EXPAREL’s intellectual property, noting 21 Orange Book-listed patents now protect the franchise across two families compared with just a single litigated patent previously. Management framed this expanded IP estate as a key strategic asset that should extend the product’s life cycle and improve its defenses against potential generic challengers.

Reimbursement Wins Expand Commercial Access

On the market access front, Pacira reported that more than 110 million covered lives now have reimbursement for EXPAREL outside the surgical bundle, aided by NOPAIN-related Medicare changes. The company also sees growing recognition among commercial payers of EXPAREL’s value in multimodal pain management, which management believes will help sustain volume growth even as pricing dynamics evolve.

Profitability, Buybacks and Balance Sheet Flexibility

Pacira delivered approximately $40.2 million of adjusted EBITDA in Q1, reinforcing its ability to invest while generating cash. The company repurchased $50 million of stock in the quarter, retiring about 2.2 million shares and bringing the share count down to 39.3 million, with another $100 million authorized, all while emphasizing that it still maintains a strong, if not precisely disclosed, balance sheet.

Manufacturing Efficiencies Support High Margins

Non-GAAP consolidated gross margin came in at a robust 80% for Q1, just below last year’s 81%, as larger-scale EXPAREL manufacturing and ongoing efficiency programs reduced unit costs. Pacira also pointed to PCRX201’s local delivery and efficient production design as a potential long-term margin contributor, suggesting future products may carry attractive cost-of-goods profiles.

GPO Discounts and Mix Weigh on Revenue Growth

Despite solid EXPAREL unit growth, reported revenue was partially muted by a shift in vial mix and higher discounts tied to a third group purchasing organization that came online last year. Management cautioned that investors should expect a similar gap between volume and revenue in Q2, with that drag narrowing around midyear as the GPO anniversary effect rolls off.

Weather-Related Disruptions Hit Q1 Sales Timing

Winter storms created logistical headaches in the quarter, disrupting shipping, prompting product returns and forcing hospitals to reschedule surgeries that typically use Pacira’s products. Management said these events tempered Q1 reported sales and will likely cause some timing shifts into subsequent periods as postponed procedures are completed and demand normalizes.

Margin Compression and Higher SG&A Spending

Pacira’s non-GAAP gross margin slipped slightly to 80%, reflecting modest margin compression as mix and discounts shifted, while SG&A rose to $83.9 million from $76.2 million. The company expects first-half SG&A to remain elevated due to proxy-related activities, with a step down in the second half, though the ongoing run-rate will still sit above prior years as commercial and corporate investments persist.

R&D Spend Ramps for Pipeline Execution

Non-GAAP R&D climbed to $25.4 million from $23.1 million, and management guided to a further step-up into the low-$30 million range in Q2 as it funds PCRX201 Part B and other programs. That spending is projected to ease back toward Q1 levels in the second half, implying a temporary increase in cash burn this year as Pacira leans into clinical catalysts that could drive medium-term value.

Policy and Market Uncertainties Around NOPAIN

Executives flagged regulatory risk tied to the NOPAIN policy, which currently supports Medicare reimbursement for EXPAREL outside the surgical bundle but is scheduled to expire in 2027. While Pacira is monitoring potential outcomes closely, management acknowledged that any changes to this construct could affect future reimbursement economics, adding an element of medium-term policy uncertainty.

Conservative Outlook for ZILRETTA and ioverao

Despite posting strong double-digit gains early in the year, ZILRETTA and ioverao are modeled conservatively in Pacira’s 2026 guidance, with expectations largely flat versus 2025. Management presented this stance as prudent, suggesting current forecasts leave room for upside if recent momentum in adoption, access and partner-driven expansion can be sustained through the remainder of the year.

Forward Guidance and Outlook

For 2026 Pacira reaffirmed total revenue guidance of $745 million to $770 million, with EXPAREL net sales of $600 million to $620 million plus about $7 million from a veterinary licensing deal. The company forecast non-GAAP gross margins of 77% to 79%, R&D of $105 million to $115 million, SG&A of $320 million to $340 million and modest margin tailwinds near term from lower-cost inventory before Q4 margins slip slightly on higher-cost stock and shutdown expenses.

Pacira’s call painted the picture of a company balancing short-term headwinds with long-term growth levers in non-opioid pain management. With EXPAREL still growing, newer products accelerating, patents reinforced and multiple clinical readouts ahead, investors were left with a narrative of disciplined execution and cautious guidance that may set the stage for upside if the pipeline and reimbursement trends hold.